169 related articles for article (PubMed ID: 37301715)
1. Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition.
Ferguson R; Chat V; Morales L; Simpson D; Monson KR; Cohen E; Zusin S; Madonna G; Capone M; Simeone E; Pavlick A; Luke JJ; Gajewski TF; Osman I; Ascierto P; Weber J; Kirchhoff T
Eur J Cancer; 2023 Aug; 189():112923. PubMed ID: 37301715
[TBL] [Abstract][Full Text] [Related]
2. Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis.
Bastacky ML; Wang H; Fortman D; Rahman Z; Mascara GP; Brenner T; Najjar YG; Luke JJ; Kirkwood JM; Zarour HM; Davar D
Front Oncol; 2021; 11():749064. PubMed ID: 34900695
[TBL] [Abstract][Full Text] [Related]
3. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma.
Pepys J; Stoff R; Ramon-Gonen R; Ben-Betzalel G; Grynberg S; Frommer RS; Schachter J; Asher N; Taliansky A; Nikitin V; Dori A; Shelly S
Neurology; 2023 Dec; 101(24):e2472-e2482. PubMed ID: 37652699
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events.
Shahabi V; Berman D; Chasalow SD; Wang L; Tsuchihashi Z; Hu B; Panting L; Jure-Kunkel M; Ji RR
J Transl Med; 2013 Mar; 11():75. PubMed ID: 23521917
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of immune checkpoint inhibitors in patients with anorectal melanoma in association with immune-related adverse events: a case series.
Yokoyama R; Sato Y; Nakamura F; Kagemoto K; Mitsui Y; Okamoto K; Kawano Y; Sogabe M; Miyamoto H; Takayama T
Clin J Gastroenterol; 2023 Dec; 16(6):842-847. PubMed ID: 37632658
[TBL] [Abstract][Full Text] [Related]
6. Safety profile of immune checkpoint inhibitors according to cancer type.
Guérin C; Laramas M; Bettega F; Bocquet A; Berton E; Lugosi M; Bouillet L; Toffart AC
Bull Cancer; 2023; 110(7-8):825-835. PubMed ID: 37225616
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
8. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors.
Sander MS; Stukalin I; Vallerand IA; Goutam S; Ewanchuk BW; Meyers DE; Pabani A; Morris DG; Heng DYC; Cheng T
Cancer Med; 2021 Apr; 10(8):2618-2626. PubMed ID: 33724676
[TBL] [Abstract][Full Text] [Related]
10. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.
Menzies AM; Johnson DB; Ramanujam S; Atkinson VG; Wong ANM; Park JJ; McQuade JL; Shoushtari AN; Tsai KK; Eroglu Z; Klein O; Hassel JC; Sosman JA; Guminski A; Sullivan RJ; Ribas A; Carlino MS; Davies MA; Sandhu SK; Long GV
Ann Oncol; 2017 Feb; 28(2):368-376. PubMed ID: 27687304
[TBL] [Abstract][Full Text] [Related]
11. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract][Full Text] [Related]
13. Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy.
Watson AS; Goutam S; Stukalin I; Ewanchuk BW; Sander M; Meyers DE; Pabani A; Cheung WY; Heng DYC; Cheng T; Monzon JG; Navani V
JAMA Netw Open; 2022 Dec; 5(12):e2245596. PubMed ID: 36480204
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles.
Ye W; Olsson-Brown A; Watson RA; Cheung VTF; Morgan RD; Nassiri I; Cooper R; Taylor CA; Akbani U; Brain O; Matin RN; Coupe N; Middleton MR; Coles M; Sacco JJ; Payne MJ; Fairfax BP
Br J Cancer; 2021 May; 124(10):1661-1669. PubMed ID: 33723392
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort Study.
van der Kooij MK; Suijkerbuijk KPM; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; van Breeschoten J; van den Eertwegh AJM; de Groot JWB; Haanen JBAG; Hospers GAP; Piersma D; van Rijn RS; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van Zeijl MCT; Wouters MWJM; Dekkers OM; Kapiteijn E
Ann Intern Med; 2021 May; 174(5):641-648. PubMed ID: 33587686
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis.
Mangla A; Lee C; Mirsky MM; Wang M; Rothermel LD; Hoehn R; Bordeaux JS; Carrol BT; Theuner J; Li S; Fu P; Kirkwood JM
JAMA Oncol; 2024 Mar; ():. PubMed ID: 38546551
[TBL] [Abstract][Full Text] [Related]
17. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.
Tarhini AA; Kang N; Lee SJ; Hodi FS; Cohen GI; Hamid O; Hutchins LF; Sosman JA; Kluger HM; Eroglu Z; Koon HB; Lawrence DP; Kendra KL; Minor DR; Lee CB; Albertini MR; Flaherty LE; Petrella TM; Streicher H; Sondak VK; Kirkwood JM
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963015
[TBL] [Abstract][Full Text] [Related]
18. Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma.
Gao CA; Weber UM; Peixoto AJ; Weiss SA
J Immunother Cancer; 2019 Oct; 7(1):262. PubMed ID: 31623673
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma.
Akturk HK; Couts KL; Baschal EE; Karakus KE; Van Gulick RJ; Turner JA; Pyle L; Robinson WA; Michels AW
JAMA Netw Open; 2022 Dec; 5(12):e2246400. PubMed ID: 36512357
[TBL] [Abstract][Full Text] [Related]
20. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis.
Xing P; Zhang F; Wang G; Xu Y; Li C; Wang S; Guo Y; Cai S; Wang Y; Li J
J Immunother Cancer; 2019 Dec; 7(1):341. PubMed ID: 31801636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]